Acute-on-chronic liver failure in cirrhosis.
Vicente Arroyo, Richard Moreau, Patrick S Kamath...
https://pubmed.ncbi.nlm.nih.gov/27277335/Actively Recruiting
Led by Shenzhen Third People's Hospital · Updated on 2026-07-17
96
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are conducting a Phase II clinical trial to evaluate the safety and efficacy of the injectable drug AS1501 in patients with acute-on-chronic liver failure ACLF. The study includes two stages Phase IIa, which is a single-arm sentinel design focusing on two dose groups, and Phase IIb, a randomized, double-blind, placebo-controlled phase to further assess treatment effects. The trial aims to determine the appropriate dosing and safety profile of AS1501 in this patient population who are in early or intermediate stages of ACLF and are not candidates for liver transplantation. In Phase IIa, participants receive a single intravenous dose of AS1501 at either 0.5 mgkg or 1 mgkg, with the first two subjects serving as sentinels for safety monitoring. Following a 20-day washout period without severe adverse events, subjects enter a multiple-dose phase receiving weekly doses for four consecutive weeks. Dose adjustments may be made based on adverse events, and additional subjects may be enrolled to maintain group sizes. Phase IIb will randomize 72 ACLF subjects to receive AS1501 at the recommended dose or placebo, with dosing schedules finalized after Phase IIa results. Participants undergo regular monitoring throughout the study, including safety assessments for adverse events and serious adverse events over 42 days. The study involves careful evaluation of liver function, infection status, and other medical conditions to ensure safety. Participants must agree to effective contraception and complete the trial protocol. The trial is sponsored by Shenzhen Third Peoples Hospital and is expected to run from June 2026 to December 2027.
CONDITIONS
Chinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patients
Q
Qiang Sun
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shenzhen Third People's Hospital
Lead Sponsor
Guangzhou 8th People's Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 6 weeks
Participants receive a single intravenous dose of AS1501 at 0.5 mg/kg or 1 mg/kg with safety monitoring. After a 20-day washout, those without severe adverse events continue weekly doses for 4 weeks. Dose adjustments and additional enrollments may occur based on safety outcomes.
Multiple visits during dosing and washout periods
Duration - Duration varies based on final protocol
Participants are randomly assigned to receive AS1501 or placebo to evaluate efficacy and safety. The dosing schedule is once weekly for 4 weeks, finalized after Phase IIa results.
Regular visits during treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Vicente Arroyo, Richard Moreau, Patrick S Kamath...
https://pubmed.ncbi.nlm.nih.gov/27277335/Shenzhen Third People's Hospital
Lead Sponsor
Guangzhou 8th People's Hospital
Collaborating Sponsor